Jennifer Lea Rutherford

US Patent:

8232394, Jul 31, 2012

Filed:

Jul 17, 2006

Appl. No.:

11/996899

Inventors:

Sally Gut Ruggeri - Waterford CT, US
Joel M. Hawkins - Old Lyme CT, US
Teresa M. Makowski - Salem CT, US
Jennifer L. Rutherford - Easton PA, US
Frank J. Urban - Old Saybrook CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 487/04

US Classification:

544280

Abstract:

This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.

US Patent:

8309716, Nov 13, 2012

Filed:

Jun 20, 2012

Appl. No.:

13/528099

Inventors:

Sally Gut Ruggeri - Waterford CT, US
Joel M Hawkins - Old Lyme CT, US
Teresa M Makowski - Salem CT, US
Jennifer L Rutherford - Gales Ferry CT, US
Frank J Urban - Old Saybrook CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 487/04

US Classification:

544280

Abstract:

This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.

US Patent:

20060030714, Feb 9, 2006

Filed:

Jul 13, 2005

Appl. No.:

11/180850

Inventors:

Jennifer Rutherford - Gales Ferry CT, US
Joel Hawkins - Old Lyme CT, US

International Classification:

C07D 213/28

US Classification:

546339000

Abstract:

This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV: respectively, wherein R, R, R, R, R, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V: respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III: wherein Rand Rare as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems. The substituted haloarenes produced by the process of the present invention are useful intermediates in the preparation of N-aryl or N-heteroaryl substituted pharmaceutically active compounds that include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT) receptors useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HTagonist or antagonist is indicated.